Clinical trials: Non Alcoholic Fatty Liver
Fatty Liver, NAFLD
The Availability of the Enhanced Liver Fibrosis (ELF) Test Affects the Rate of Diagnosis of Nonalcoholic Steatohepatitis (NASH) With Fibrosis in Patients Referred to Hepatology
Background: During the hepatology evaluation, vibration-controlled transient elastography (VCTE) is often used as a clinical decision aid to target high-risk patients for liver biopsy.
- Trial name
- NCT05370053
- Testing
- ELF Test
- Where
- United States
- Volunteers
- 450 people
- Sponsor
- University of Kansas Medical Center
Non-alcoholic Fatty Liver Disease (NAFLD)
Assessment of Hepatic Steatosis Using Dedicated Software Implemented on Ultrasound Devices
Non-alcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease, with an estimated prevalence of 5-30% in the general population and 55-80% in patients with type 2 diabetes.
- Trial name
- NCT07268937
- Testing
- CAP (Controlled Attenuation Parameter) module implemented on the Fibroscan machine.
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Nonalcoholic Steatohepatitis (NASH)
A Phase I Clinical Trial of XZP-5610 Tablets in Healthy Subjects
This study will consist of 3 parts: Part A - Single Ascending Dose (SAD) phase, Part B - multiple ascending dose (MAD) phase, and Part C - Food Effect (FE) phase.
- Trial name
- NCT04913090
- Testing
- XZP-5610 Tablet (for Part A), XZP-5610 Tablet (for Part B), XZP-5610 Tablet （for "Part C1"）
- Where
- China
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
Non-Alcoholic Fatty Liver Disease
Berberine and Non-Alcoholic Fatty Liver Disease (NAFLD)
Non-alcoholic fatty liver disease (NAFLD), one of the most common liver dysfunctions, affects about one-fourth of the global adult population and has a significant mortality rate between 6.3% and 33%.NAFLD can lead to other…
- Trial name
- NAFLD (NCT04049396)
- Testing
- Berberine
- Where
- Iran
- Volunteers
- 50 people
- Sponsor
- Lida Nejati
Non-Alcoholic Steatohepatitis
A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH
A randomized, double-blind study to assess the safety and efficacy of EDP-305 in subjects with liver-biopsy proven Non-Alcoholic Steatohepatitis (NASH)
- Trial name
- NCT04378010
- Testing
- EDP-305 1.5 mg, EDP-305 2 mg
- Where
- 81 sites in United States, Argentina and 4 more
- Volunteers
- 98 people
- Sponsor
- Enanta Pharmaceuticals, Inc
Non-Alcoholic Fatty Liver Disease
Tocotrienol as a Treatment for Non-alcoholic Fatty Liver Disease
Vitamin E's potential in treating non-alcoholic fatty liver disease (NAFLD) is attributed to its antioxidant properties. While tocopherols have shown significant results in NAFLD management, the powerful properties of…
- Trial name
- NCT06596382
- Testing
- Tocotrienol rich-vitamin E
- Where
- Malaysia
- Volunteers
- 264 people
- Sponsor
- National University of Malaysia
MASH, NASH
A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis
A randomized, double-blind, placebo-controlled Phase 3 study to determine if denifanstat 50 mg or 25 mg is effective, as compared to placebo, in resolving MASH without the worsening of fibrosis and/or in fibrosis regression…
- Conditions
- MASH, NASH, Metabolic Dysfunction-associated Steatohepatitis, Noncirrhotic Metabolic Dysfunction-associated Steatohepatitis
- Trial name
- FASCINATE-3 (NCT06594523)
- Testing
- Denifanstat
- Sponsor
- Sagimet Biosciences Inc.
Nonalcoholic Steatohepatitis
Using Hydroxychloroquine to Treat Nonalcoholic Steatohepatitis
Nonalcoholic steatohepatitis (NASH) is a serious type of nonalcoholic fatty liver disease (NAFLD), which is characterized by lobular inflammation and apoptosis resulting from hepatic steatosis in the absence of excessive alcohol…
- Trial name
- NCT05733897
- Testing
- hydroxychloroquine
- Where
- 2 sites in Taiwan
- Volunteers
- 150 people
- Sponsor
- National Taiwan University Hospital
Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis
Structured Mobile Technology Based Lifestyle Program vs Usual Care for Patients With Non-alcoholic Fatty Liver Disease
This study will look at physical activity and nutrition in patients with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).
- Trial name
- NCT03839082
- Testing
- Usual Care then FitBit, FitBit then Usual Care
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Michigan
NAFLD, NASH
THE FRENCH NATIONAL NAFLD COHORT (FRench pAtients With MEtabolic Steatosis)
The main objective of this cohort study is to determine genetic, clinical biologic and metabolic factors associated with patient heterogeneity in regards to severity of NAFLD at diagnosis as well as during the clinical course.
- Conditions
- NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis
- Trial name
- FRAMES (NCT04925362)
- Testing
- Biological specimens, Additional visit
- Volunteers
- 900 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Non-Alcoholic Fatty Liver Disease, NAFLD
Economic Burden of NAFLD
To determine the economic burden of NAFLD (Non-Alcoholic-Fatty-Liver Disease) patients in Belgium, Flanders by means of a bottom-up approach.
- Trial name
- NCT05035043
- Testing
- Determination of the economic burden NAFLD patients
- Where
- Belgium
- Volunteers
- 73 people
- Sponsor
- Hasselt University
HIV Infections, Fatty Liver
Non-alcoholic Fatty Liver Disease (NAFLD) in HIV: The Role of Nutritional Interventions
The purpose of this study is to evaluate the effect of a one-year nutritional intervention with either betaine or vitamin E supplementation, or a weight reducing diet and exercise program on liver steatosis and steatohepatitis.
- Trial name
- NCT00152815
- Testing
- antioxidant vitamin E, weight reduction and exercise
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Johane Allard
Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome
Dairy Protien Rich Diet for NAFLD Patients
The overarching aim of this project is to investigate effects of dietary interventions on nonalcoholic fatty liver disease (NAFLD) severity and to delineate the relationship with improvements in metabolic aberrations in liver…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome, Caseins, Whey
- Trial name
- DAIPRO-NAFLD (NCT04841915)
- Testing
- High-Protein Diet, Clinical dietician, Weight loss
- Where
- 2 sites in Denmark
- Volunteers
- 46 people
- Sponsor
- University of Aarhus
Non-Alcoholic Fatty Liver Disease
Cold-induced Brown Fat Activation and Hepatic Steatosis
In the recent years, research on brown adipose tissue (BAT) revealed that larger amounts as well as higher activity thereof are associated with a favourable metabolic phenotype.
- Trial name
- NCT03811236
- Testing
- Cold exposure
- Where
- Austria
- Volunteers
- 26 people
- Sponsor
- Medical University of Vienna
Overweight or Obesity
Soy Peptide, Conjugated Linoleic Acid, Overweight or Obese, Body Composition
Soybean peptides are a mixture of active peptides obtained from the hydrolysis of soybean protein, which have biological activities such as antioxidant, blood pressure lowering, anti-fatigue and lipid lowering, etc.
- Trial name
- NCT04728399
- Testing
- Experimental group, Control group
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fangfang Zeng
Cardiovascular Disease
The Impact of Almond Nut Consumption on Markers of CVD & Metabolic Health
The purpose of this study is to investigate the cardio-metabolic health effects of consuming almond nuts in place of habitual (usual) snack products in adults at moderate risk of developing cardiovascular disease
- Trial name
- Almonds (NCT02907684)
- Testing
- Almonds, Muffins/Crackers
- Where
- United Kingdom
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- King's College London
Non-alcoholic Fatty Liver Disease
Serine Supplementation for Obese Subjects With Fatty Liver Disease
In this study, the investigators aim to increase the liver tissue level of GSH in NAFLD patients by short-term dietary serine supplementation and improve their liver function by lowering the oxidative stress resulting from…
- Trial name
- NCT02599038
- Testing
- Serine supplementation
- Where
- 2 sites in Sweden
- Volunteers
- 10 people
- Sponsor
- Hanns-Ulrich Marschall
Type2 Diabetes, NAFLD
Effects of VLCD and Bariatric Surgery in Patients With Type 2 Diabetes
The investigators are therefore interested to explore the effects of VLCD and different bariatric surgery procedures to changes in the physical deposition of fat in organs which regulate glucose metabolism (i.e.
- Conditions
- Type2 Diabetes, NAFLD, Obesity
- Trial name
- BARIATRICMRI (NCT05092399)
- Testing
- Bariatric Surgery
- Where
- United Kingdom
- Volunteers
- 21 people
- Sponsor
- University of Nottingham
Non-alcoholic Fatty Liver Disease (NAFLD)
Non Alcoholic Fatty Liver Disease Influence of Statin Therapy
Aim: 1. To determine the prevalence of fatty liver in a cohort of patients hospitalized with chest pain in the Cardiology department. 2.
- Trial name
- NCT00375349
- Testing
- Ultrasound to demonstrate existence of fatty liver
- Sponsor
- Shaare Zedek Medical Center
Fatty Liver, Nonalcoholic
Development of a Novel Asian Mediterranean Diet and Its Acceptability in NAFLD
The goal of this pre-intervention study is test the acceptability of Asian version of the Mediterranean diet to NAFLD patients. The main question[s] it aims to answer are: 1.
- Trial name
- aMed (NCT06321211)
- Where
- Singapore
- Volunteers
- 30 people
- Sponsor
- Singapore Institute of Technology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.